Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

SGLT2 Inhibitor, an Agent for Diabetes, Heart, Kidney... and Stroke

  • Taeil Yang (Division of Cardiology, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine) ;
  • Jooyeon Lee (Division of Cardiology, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine) ;
  • Jaewon Oh (Division of Cardiology, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine)
  • Received : 2024.07.01
  • Accepted : 2024.07.24
  • Published : 2024.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Lim CS. End-stage kidney disease fact sheet 2024. Seoul: The Korean Society of Nephrology; 2024. p. 9-10.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:S117-314.
  3. Oh J, Lee SH, Lee CJ, Kang SM. Sodium-glucose co-transporter 2 inhibitors: a new path for heart failure treatment. Korean Circ J 2021;51:399-408.
  4. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care 2023;46:S140-57.
  5. McDonagh TA, Metra M, Adamo M, et al. Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:4901.
  6. Felix N, Gauza MM, Teixeira L, et al. Cardiovascular outcomes of sodium-glucose cotransporter-2 inhibitors therapy in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and updated meta-analysis. Korean Circ J 2024;54:549-61.
  7. Imprialos KP, Boutari C, Stavropoulos K, Doumas M, Karagiannis AI. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry 2017;88:249-53.
  8. Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2021;11:15364.
  9. Chang SN, Chen JJ, Huang PS, et al. Sodium-glucose cotransporter-2 inhibitor prevents stroke in patients with diabetes and atrial fibrillation. J Am Heart Assoc 2023;12:e027764.
  10. Koshino A, Schechter M, Chertow GM, et al. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid 2023;2:EVIDoa2300049.